Clinical Research and Trials—A “Nonessential” Victim of the COVID-19 Pandemic?

• Published in: The American journal of gastroenterology Vol. 115; no. 6; pp. 946 - 947
• Main Authors: Peyrin-Biroulet, Laurent, Ananthakrishnan, Ashwin N.
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer 01.06.2020; Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins; Lippincott, Williams & Wilkins
• Subjects: Betacoronavirus - isolation & purification; Black swan event; Clinical trials; Clinical Trials as Topic - organization & administration; Colonoscopy; Coronavirus Infections - epidemiology; Coronavirus Infections - prevention & control; Coronavirus Infections - transmission; Coronaviruses; Correspondence; COVID-19; Disease transmission; Disease Transmission, Infectious - prevention & control; Emerging diseases; Gastroenterology; Gastroenterology - methods; Human health and pathology; Humans; Infection Control - methods; Inflammatory bowel disease; Life Sciences; Microbiology and Parasitology; Pandemics; Pandemics - prevention & control; Patient Care Management - methods; Patient Care Management - standards; Patients; Pneumonia, Viral - epidemiology; Pneumonia, Viral - prevention & control; Pneumonia, Viral - transmission; Research Subjects; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Virology
• ISSN: 0002-9270; 1572-0241; 1572-0241
• DOI: 10.14309/ajg.0000000000000663

Often, these are patients who have experienced prolonged disease-related morbidity in addition to potential treatment-related effects (such as with persistent corticosteroid use in patients with inflammatory bowel disease [IBD]). [...]solutions could include greater use of remote or teleconsenting of patients and secure digital platforms for conducting assessment and follow-up visits, which would be of enormous value not only in this particular situation but also aid in making participations in a trial more appealing to participants even at other times. L.P.-B. has received personal fees from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boehringer Ingelheim, Pfizer, InDex Pharmaceuticals, Sandoz, Celgene, Biogen, Samsungbioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance, grants from Abbvie, MSD, Takeda, and stock options from CTMA.